What Is GLP-1?

GLP-1 stands for Glucagon-Like Peptide-1 — a hormone naturally produced in your gut after you eat. When food reaches your small intestine, specialized cells called L-cells release GLP-1 into your bloodstream. This hormone then acts on multiple organs simultaneously to coordinate your body's response to food.

In a healthy person, GLP-1 does several things at once: it tells the pancreas to release insulin, it stops the liver from dumping glucose into the blood, it slows how quickly food leaves the stomach, and it signals the brain that you've eaten enough. It's essentially a master coordinator of the feeding response.

The problem is that natural GLP-1 is extremely short-lived — it's broken down by an enzyme called DPP-4 within minutes of being released. This makes the natural hormone impractical as a treatment. GLP-1 receptor agonist medications solve this by being engineered to resist degradation, lasting days to weeks in the body.

168x
Longer half-life than natural GLP-1. Semaglutide has a half-life of approximately 1 week, compared to just minutes for the body's naturally produced GLP-1 hormone. This is what makes weekly injections possible.

How GLP-1 Medications Cause Weight Loss

The weight loss from GLP-1 medications comes primarily from reduced calorie intake, not from burning more calories. These drugs don't significantly increase metabolism — they make it dramatically easier to eat less by fundamentally changing how hungry you feel.

Three mechanisms drive most of the weight loss effect:

1. Gastric Emptying Slowdown

When food sits in your stomach longer, you feel full sooner and stay full longer. A meal that previously kept you satisfied for 2 hours might now keep you satisfied for 4. For many patients, this is the most immediately noticeable effect — eating a small portion and genuinely feeling satisfied rather than still wanting more.

2. Hypothalamic Appetite Suppression

GLP-1 receptors are expressed in the hypothalamus — the brain region that regulates hunger and satiety. When these receptors are activated, hunger signals diminish significantly. Many GLP-1 users describe a profound change in their relationship with food: the constant background noise of hunger that they'd experienced for years simply quiets down.

3. Reward System Modulation

Perhaps the most scientifically fascinating mechanism: GLP-1 receptors are also present in the brain's reward system, particularly in areas that generate the pleasure response to eating. Activating these receptors appears to reduce the hedonic drive to eat — the "food noise" that drives people to eat beyond satiety, especially of ultra-processed, high-fat, high-sugar foods.

The "food noise" phenomenon: Many GLP-1 users report that the constant mental preoccupation with food — planning the next meal, craving snacks, thinking about eating even when not hungry — dramatically decreases or disappears entirely on these medications. This is distinct from willpower and reflects real neurobiological changes in how the brain processes food-related stimuli.

Semaglutide vs Tirzepatide: Why One Works Better

Understanding the mechanism difference between semaglutide and tirzepatide explains why tirzepatide produces more weight loss on average.

Semaglutide (Ozempic, Wegovy) is a GLP-1 receptor agonist — it activates only the GLP-1 receptor pathway described above.

Tirzepatide (Mounjaro, Zepbound) is a dual GIP/GLP-1 receptor agonist. In addition to activating GLP-1 receptors, it also activates GIP (Glucose-dependent Insulinotropic Polypeptide) receptors. GIP is another gut hormone that regulates insulin release and fat storage, and its receptors are also present in the brain's appetite centers.

By activating both pathways simultaneously, tirzepatide produces additive effects on appetite suppression and metabolic improvement. Clinical trials confirm this: the SURMOUNT-1 trial showed tirzepatide at 15mg produced an average 22.5% body weight loss — the highest ever recorded in a pharmaceutical obesity trial. See the full Semaglutide vs Tirzepatide comparison for more.

How GLP-1 Drugs Treat Diabetes

GLP-1 medications were originally developed for type 2 diabetes management, where their blood sugar-lowering effects are the primary goal. The mechanisms are direct and well-established:

  • Glucose-stimulated insulin secretion: GLP-1 agonists stimulate the pancreatic beta cells to release insulin — but only when blood glucose is elevated. This "glucose-dependent" mechanism means they rarely cause hypoglycemia (dangerous low blood sugar), unlike some older diabetes medications.
  • Glucagon suppression: They reduce glucagon secretion from the pancreatic alpha cells. Glucagon tells the liver to release stored glucose — suppressing it lowers fasting blood sugar.
  • Reduced hepatic glucose output: Less glucagon means the liver produces less glucose, which reduces fasting blood sugar levels throughout the day.

For people with type 2 diabetes, these effects typically produce a significant reduction in HbA1c (a measure of average blood sugar over 3 months), often in the range of 1–2 percentage points. See our GLP-1 and Diabetes guide for a full breakdown.

Cardiovascular Benefits

One of the most important and surprising findings about GLP-1 medications is their cardiovascular benefit — beyond what would be expected from weight loss alone. The LEADER trial (liraglutide) and SELECT trial (semaglutide) both showed significant reductions in major cardiovascular events including heart attack and stroke in high-risk patients.

The mechanisms behind these benefits are still being studied but likely include direct anti-inflammatory effects on blood vessel walls, reduced blood pressure, improved lipid profiles, and reduced fat accumulation in the liver. The SELECT trial showed semaglutide reduced cardiovascular events by approximately 20% in patients with obesity but without diabetes — a landmark finding that broadened the clinical view of these medications.

Why Weight Loss Slows and Plateaus

Almost everyone on GLP-1 medications experiences a weight loss plateau — a period where loss stalls despite continued medication. This isn't the drug "stopping working." It's the body's natural metabolic adaptation responding to the new lower weight.

When you lose significant weight, your body responds in multiple ways: it reduces its basal metabolic rate (burns fewer calories at rest), it increases appetite-stimulating hormones like ghrelin, and it becomes more metabolically efficient. The medication continues to suppress appetite, but the body's compensatory mechanisms partially offset the effect.

This plateau is expected and normal. Use our Plateau Calculator to estimate when it might occur for you, and our Weight Loss Predictor to see your full projected timeline.